5 results about "Asthma symptoms" patented technology

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention discloses a ginsenoside composition and an application thereof, and particularly relates to an application of the ginsenoside composition in preparation of a medicine for treating asthma. The core of the composition is that the composition comprises the following components in specific parts by weight: 4-8 parts of ginsenoside Rg1 and 1-3 parts of ginsenoside Rb1, and 2-4 parts of total ginsenoside which takes effect together with one of the ginsenoside Rg1 and the ginsenoside Rb1 and is prepared through standardization, and the total content of the Rg1 and the Rb1 in the total ginsenoside is 50-70%. According to the present invention, the known pure saponin product and the standardized total saponin rich in the specific unknown saponin group are combined according to the specific ratio so as to produce the unexpected synergistic effect; pharmacodynamic experiments prove that the composition can significantly improve asthma symptoms and effectively inhibit airway inflammation, mucus hypersecretion and immune imbalance, and the curative effect of the composition is significantly superior to that of a single component or common total saponins. Meanwhile, the product quality is stable and controllable through a specific extraction and purification process.

The invention belongs to the technical field of biological medicines, and particularly relates to application of xanthohumol in preparation of a medicine for relieving allergic rhinitis and asthma symptoms. By constructing an animal model and a cell model, results show that xanthohumol can be successfully absorbed and metabolized by a digestive tract to play a biological role, and OVA-induced allergic airway inflammatory response can be remarkably improved. Compared with a disease model group, the xanthohumol can reduce the proportion of inflammatory cells in peripheral blood and BALF of mice and improve the infiltration condition of eosinophilic granulocytes in lung tissues. In addition, xanthohumol can regulate Th cell balance and cell factor release in mouse lung tissue. The oxidative stress state represented by OVA-induced ROS level rise causes the release of dsDNA and the activation of AIM2 inflammasome-related protein to be an important mechanism for mediating allergic airway inflammatory reaction, and the expression can be obviously improved by xanthohumol, so that a potential target and an effective strategy are provided for clinical treatment in the future.

The invention discloses application of a target expression inhibitor to preparation of a medicine for preventing and treating asthma. The invention discovers that the expression of OR5W2 in an asthma cell model is significantly up-regulated, the overexpression of OR5W2 can significantly promote the expression of IL-33 and CCL20 in the asthma cell model, and the knock-down of OR5W2 can significantly inhibit the expression of IL-33 and CCL20 in the asthma cell model. Technicians in the field know that IL-33 and CCL20 are key factors for causing a series of asthma symptoms, when a body inhales allergens, airway epithelial cells can secrete chemotactic factors CCL20 to attract mononuclear cells and immature dendritic cells into the lung, meanwhile, IL-33 is secreted to activate the lung dendritic cells and promote Th2-type immune response, and therefore, the lung is prevented from being infected by the lung. A series of asthma symptoms are further caused. Therefore, the OR5W2 expression inhibitor has the prospect of being developed into the medicine for preventing and treating asthma.